Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Antitumor Activity of 7-[2-(N-Isopropylamino)ethyl]-(20s)-camptothecin, CKD602, as a Potent DNA Topoisomerase I Inhibitor

  • Lee, Jun-Hee (Chong Kun Dang Research Institute, Chong Kun Dang Corp.) ;
  • Lee, Ju-Mong (Chong Kun Dang Research Institute, Chong Kun Dang Corp.) ;
  • Kim, Joon-Kyum (Chong Kun Dang Research Institute, Chong Kun Dang Corp.) ;
  • Ahn, Soon-Kil (Chong Kun Dang Research Institute, Chong Kun Dang Corp.) ;
  • Lee, Sang-Joon (Chong Kun Dang Research Institute, Chong Kun Dang Corp.) ;
  • Kim, Mie-Young (College of Pharmacy, Chung-Ang Univ.) ;
  • Jew, Sang-Sup (College of Pharmacy, Seoul National University) ;
  • Park, Jae-Gab (Seoul National Univ. Cancer Research Center) ;
  • Hong, Chung-Il (Chong Kun Dang Research Institute, Chong Kun Dang Corp.)
  • Published : 1998.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

We developed a novel water-soluble camptothecin analobue, CKD602, and evaluated the inhibition of topoisomerase I and the antitumor activities against mammalian tumor cells and human tumor xenografts. CKD602 was a nanomolar inhibitor of the topoisomerase I enzyme in the cleavable complex assay. CKD602 was found to be 3 times and slightly more potent than topotecan and camptothecin as inhibitors of topoisomerase, respecitively. In tumor cell cytotoxicity, CKD602 was more potent than topotecan in 14 out of 26 human cancer cell lines tested, while it was comparable to camptothecin. CKD602 was tested for the in vivo antitumor activity against the human tumor xenograft models. CKD602 was able to imduce regression of established HT-29, WIDR and CX-1 colon tumors, LX-1 lung tumor, MX-1 breast tumor and SKOV-3 ovarian tumor as much as 80, 94, 76, 67, 87% and 88%, respectively, with comparable body weight changes to those of topotecan. Also the therapeutic margin (R/Emax: maximum tolerance dose/$ED-{58}$) of CKD602 was significantly higher than that of topotecan by 4 times. Efficacy was determined at the maximal tolerated dose levels using schedule dependent i.p. administration in mice bearing L1210 leukemia. On a Q4dx4 (every 4 day for 4 doses) schedule, the maximum tolerated dose (MTD) was 25 mg/kg per administration, which caused great weight loss and lethality in <5% tumor bearing mouse. this schedule brought significant increase in life span (ILS), 212%, with 33% of long-term survivals. The ex vivo antitumor activity of CKD602 was compared with that of topotecan and the mean antitumor index (ATI) values recorded for CKD602 were significantly higher than that noted for topotecan. From these results, CKD602 warrants further clinical investigations as a potent inhibitor of topoisomerase I.

Keywords

References

  1. Biotechnology v.6 Topoisomerases as novel targets for cancer chemotherapy Bodley;A.L.;Liu;L.F.
  2. Cacer Chemother. Rep. v.56 Plasma camptothecin(NSC-100880)levels during a 5-day course of treatment:relation to dose and toxicity Creaven;P.J.;Allen;L.M.;Muggia;F.M.
  3. Cancer Res. v.34 Lethal activity of camptothecin sodium on human lymphoma cells Drewinko;B.;Freirech;E.J.;Gottlieb;J.A.
  4. Science v.246 DNA topoisomerase I- targeted chemotherapy of human colon cancer in xenografts Giovanella;B.C.;Stehlin;J.S.;Wall;M.E.;Wani;M;C;Nicholas;A.W.;Liu;L.F.;Silber;R.;Potmrsil;M.
  5. Cancer Chemother. Rep. v.54 Preliminary pharmacologic and clinical evaluation of campyothecin sodium(NSC-100880) Gottlieb;J.A.;Guarino;A.M.;Call;J.B.;Oliverio;V.;Block;J.B.
  6. Cancer Chemother. Rep. v.56 Treatment of malignant mrelanoma with camptothecin(NSC-100880) Gottlieb;J.A.;Luce;J.K.
  7. Cancer Res, v.48 Identification of mammalian DNA topoisomerse I as intracellular taeget of the anticancer drug camptothecin Hsiang;Y.H.;Liu;J.F.
  8. J. Biol. Chem. v.260 Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I Hsiang;Y.H.;Hertzberg;R.;Hech;S.Liu;L.F.
  9. Cancer Res. v.49 Arrest of replication forks by drug-stabilized opoisomerase IDNA cleavable complexes as a mechanism of cell killing by camptothecin Hsiang;Y.H.;Wu;H.Y.;Liu;L.F.
  10. Biochem. Pharmacol. v.37 Ropoisomerases:novel therapeutic targets in cancer chemotherapy Hsiang;Y.H.;Wu;H.Y.;Liu;L.F.
  11. Bioorg. Med. Chem. v.6(7) Synthesis and antiumor activity of 7-substituted 20(R.S)-camptothecin analogues Jew;S.S.;Kim;H.J.;Kim;M.G.;Roh;E.Y.;Cho;Y.S.;Kim;J.K.;Cha.k.h.;Lee;K.K.;Han;H.J.;Choi;J.Y.;Lee;H.S.
  12. Bioorg. Med. Chem. Lett. v.6 Synthesis and in vitro cytotoxicity of (R.S)-20-desethyl-20-substitued camptothecin analogues Jew;S.S.;Kim;M.G.;Kim;H.J.;Roh;E.Y.;Cho;Y.S.;Kim;J.K.;Cha.k.h.;Lee;K.K.;Han;H.J.;Lee;H.S.
  13. Tetrahedron:Asymmetry v.6 Enantioselective sybthesis of 20(S)-camptothecin using sharpless catalytic asymmetric dihydroxylation Jew;S.S.;Ok;K.D.;Kim;H.J.;Kim;M.G.;Kim;J.M.;Hah;J.M.;Cho;Y.S.
  14. J. Med. Chem. v.34 Synthesis of water-soluble(aminoalkyl)camptothecin analogues:Inhibition of topoisomerase I and antitumor activity Kingsbury;W.D.;Boehm;J.C.;Jakas;D.R.
  15. KRICT report-PartⅠ (unpublished data):Acute toxicity study of CKD-602 in rats
  16. KRICT report-Part Ⅱ(unpublished data):4 weeks subacute toxicity study of CKD-602 in rats
  17. Proc. Am. Assoc. Cancer Res. v.39 no.303 Antitumor activity of CKD602;a novel camptothecin derivative Lee;J.H.;Sohn;Y.S;Lee;J.M.;Kim;J.K.;Ahn;S.K.;Jew;S.S.;Park;J.G.;Hong;C.I.
  18. Cancer Res. v.32 Li;L.H.;Fraser;T.J.;Olin;E.J.;Bhuyan;B.K. Action of camptothecin on mammalian cells in culture
  19. J.Biol. Chem. v.258 Cleavage of DNA by mammalian DNA topoisomerase Ⅱ Liu;L.F.;Rowe;T.C.;Tang;J.;Tewey;K.M.;Chen;G.L.
  20. Cancer Chemother. Rep. v.56 Phase Ⅱ study of camptothecin(NSC-100880) in the treatment of advannced gastriotestinal cancer Moertel;C.G.;Scutt;A.J.;Reutemeier;R.J.;Hahn;R.G.
  21. Cancer Chemother. Rep. v.56 PhaseⅠclinical trial of weekly and daily treatment with camptothecin(NSC-100800):correlation with preclinical studies Muggia;F.M.;Creaven;P.J.;Hansen;H.H.;Cohen;M.H.;Selawry;O.S.
  22. publacation nunber:WO96-21666;Camptothecin ferative and its manufacturing method Patent
  23. FASEB J. v.2 DNA topoisomerases as targets for chemotherapy Rose K.M.
  24. Cancer Chamother. Pharmacol. v.27 Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay sASAKI;Y.;Shinkai;T.;Eguchi;K.;Tamura;T.;Ohe;Y.;Ohmori;T.;SaijO;N.
  25. Cancer Chemother. Rep. v.54 Implications of biochemical;cytokinetic;pharmacologic;and toxicologic relationships in the design of optimal schedules Skipper;H.E.;Schabel;F.M.;Jr;Mellett;L.B.;Montgomerry;J.A.;Wilkoff;L.J.;Lloyd;H.H.;Brockman;R.W.
  26. J. Am. Chem. Soc. v.83 Plant antitumor agents I:The isolation and structure of camptothecin;a novel alkaloidal leukemia and tumor inhibition from Camptotheca acuminata. Wall;M.E.;Wani;M.C.;Cook;C.E.;Pa;mer;K.H.;Mcphail;A.T.;Sim;G.A.